

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcements of GenScript Biotech Corporation (the “**Company**”) dated 14 May 2021 in respect of the discloseable transactions and resumption of trading (the “**first announcement**”) and the announcement of the Company dated 14 May 2021 in respect of the issue of new shares under general mandate (the “**second announcement**”).

The Company would like to clarify that there were two inadvertent clerical errors where (i) in the first announcement, the timing for resumption of trading should be read as “1:00 p.m.” instead of “13:30 p.m.”, and (ii) in the Chinese version of the second announcement, gross proceeds from the Subscription (as defined therein) are expected to be approximately HK\$1,921,435,413.27 instead of US\$1,921,435,413.27.

Save as disclosed in this announcement, all information set out in the first announcement and the second announcement remain unchanged.

By order of the Board
Genscript Biotech Corporation
Meng Jiange
Chairman and Executive Director

Hong Kong, 14 May 2021

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* For identification purposes only